| Expression pattern: |
DN |
| Associated gene: |
- |
| Associated microRNA: |
- |
| Biological function: |
Plasma hsa_circ_0001445 acts as a blood-based biomarker of stable CAD and is inversely associated with coronary atherosclerotic burden; lower levels indicate greater coronary atherosclerosis extent and severity. |
| Molecular mechanism: |
The study suggests that coronary smooth muscle cells may contribute to reduced circulating hsa_circ_0001445 through decreased secretion/unloading into extracellular vesicles under atherogenic conditions; no causal molecular pathway was established. |
| Biological pathway or process: |
other pathway/process (other) |
| Detected method: |
Q
|
| Validation methods: |
Back-Splice Junction PCR / divergent primers PCR; Sanger Sequencing; RT-qPCR; Clinical Sample Validation; ROC Analysis; Bioinformatics Analysis |
| Clinical significance: |
Plasma hsa_circ_0001445 provides additional useful information beyond conventional clinical risk factors and may help predict coronary atherosclerotic burden in suspected stable CAD. |
| Description: |
This study evaluated plasma hsa_circ_0001445/circSMARCA5 as a circulating biomarker for stable coronary artery disease. Lower plasma levels were associated with higher coronary atherosclerotic burden and improved patient reclassification when added to clinical risk models. In vitro experiments suggested that atherogenic conditions reduce hsa_circ_0001445 levels in extracellular vesicles secreted by human coronary smooth muscle cells. |
| Confidence score: |
0.6238 |